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Open access under CC BYThe unraveling of cellular apoptosis machinery provides novel targets for cancer treatment, and gene
therapy targeting this suicidal system has been corroborated to cause inﬂammation-free autonomous
elimination of neoplastic cells. The apoptotic machinery can be targeted by introduction of a gene encod-
ing an inducer, mediator or executioner of apoptotic cell death or by inhibition of anti-apoptotic gene
expression. Strategies targeting cancer cells, which are achieved by selective gene delivery, speciﬁc gene
expression or secretion of target proteins via genetic modiﬁcation of autologous cells, dictate the out-
come of apoptosis-based cancer gene therapy. Despite so far limited clinical success, gene therapy target-
ing the apoptotic machinery has great potential to beneﬁt patients with threatening malignancies
provided the availability of efﬁcient and speciﬁc gene delivery and administration systems.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.9–11Introduction
Gene therapy is the deﬁnitive therapeutic practice involving the
transferring of DNA or RNA directly to in vivo cells, or to isolated
cells followed by reinfusion of these cells into human body.1 Given
that cancers are among the most severe threats to human health
due to the unsatisfactory efﬁcacy and inevitable systemic toxicity
of traditional radio- and chemo-treatment, gene therapy has found
its footing in treatment of neoplasia of divergent tissues.2 Cancer
cells could be modiﬁed with the genes of cytotoxic or tumor sup-
pressor proteins, or with a class of suicidal genes in combination
with prodrugs, all of which result in autonomous cell death.3,4
Alternatively, the antitumor immune response could be elicited
by genetic modiﬁcation of malignant cells or immune cells to pro-
duce cytokines or tumor antigens.5,6 However, considering the rel-
atively weak immune levels in cancer patients, strategies that
directly kill tumor cells are advantageous in the context of micro-
environments educated by tumors.7
Whereas cytotoxic proteins like bacteria-derived toxins are
capable of triggering cell death via diverse mechanisms, they fre-
quently cause uncontrolled inﬂammation due to strong immuno-
genicity.8 Thanks to our ever clearer understanding of apoptosis
in recent years, oncologists are currently able to utilize this self-en-f Biochemistry and Molecular
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-NC-ND license.emy system to eliminate neoplastic cells. Apoptosis is pro-
grammed cell death characterized by a series of morphological
and biochemical changes which is attributed to accurately regu-
lated molecular events or signaling cascades.9 In fact, doctors had
achieved apoptosis of tumor cells via traditional treatment much
earlier than they were aware of that.11 While both chemo- and
radio-therapy caused massive apoptosis of tumor cells, they also
undistinguishably kill normal cells.11,12 Therefore, the establish-
ment of targeted pro-apoptotic therapeutic protocols or the devel-
opment of apoptosis-inducing drugs that target the tumor without
causing severe impairment of the normal organism has been under
way since the 1990s, and has provided novel approaches to the
successful treatment of cancers.13,14
Canonical apoptotic machinery in mammalian cells
Cells undergoing apoptosis exhibit hallmarks of morphological
abnormalities, e.g. shrunken and bubbled cytoplasm, condensed
nucleus, fragmented chromatin but intact membrane or organelle
at the early stage.15 Apoptosis is triggered by extracellular or intra-
cellular stimuli, and thereafter the intracellular signaling, which
ultimately leads to the degradation of functional proteins, collapse
of cytoskeletons and fragmentation of DNA.16
Death receptor-mediated extrinsic signal pathway
Death receptors are a class of transmembrane receptors belong-
ing to the tumor-necrosis factor receptor (TNFR) superfamily.
These receptors bind to ligands of a homotrimeric TNF protein fam-
ily, e.g. Fas ligand (FasL or CD95L).17 The association of FasL with
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sequently recruits the adaptor molecule, Fas-associated death do-
main (FADD), via interaction between their death domains (DD).
FADDs bind and activate FADD-like interleukin-1b-converting en-
zyme (FLICE), also known as caspase-8, via their death effector do-
mains (DED), followed by a cascade of cysteine aspartate protease
(caspase) activation and ultimately the cleavage of protein sub-
strates.17–19 Caspases are concerved executioners of apoptosis,
existing as zymogens in mammalian cells. Upon activation, caspas-
es recognize speciﬁc protein substrates and cleave them at certain
amino acid motif after an aspartate residue. Caspases are classiﬁed
into two types based on their roles in apoptotic signaling: initiator
(apical) caspases like caspases-2, -8, -9, -10 and -12, and effector
caspases including caspases-3, -6 and -7.19,20 Initiator caspases like
the aforementioned caspase-8 are activated by upstream apoptotic
signaling to initiate a cascade of caspase activation. They could
process and activate effector caspases, which in turn cleave diver-
gent protein substrates involved in cell structure maintenance,
metabolism and physiological functions (Fig. 1).19,21
In addition to the well-documented FasL/Fas pathway, the roles
of other death receptors in apoptotic signaling have also been
established.18,22,23 In response to TNF engagement, TNFR1 interacts
with various death domain-containing proteins to form a complex
consisting of the adaptor, TNF receptor 1 associated via death do-
main (TRADD). While the complex preferably bind I-kappaB-kinase
(IKK) to activate nuclear factor-kappaB (NF-jB) and promote cell
survival, TRADD could also recruit other adaptors like FADD and
RAIDD, which consequently trigger apoptosis via activation of cas-
pase-8 and caspase-2, respectively.22,23 The TNF-related apoptosis-
inducing ligand (TRAIL) could bind 5 death receptors: TRAIL-R1 to
TRAIL-R5. While TRAIL-R1 and TRAIL-R2 contain the death domain
and are capable of inducing apoptosis via the FADD/caspase-8
pathway, the other three receptors, TRAIL-R3 to TRAIL-R5 serve
as ‘‘decoy receptors’’ since they are deﬁcient in downstream signal-
ing and actually suppress apoptosis by competitively binding to
TRAIL (Fig. 1).24,25Fig. 1. The extrinsic and intrinsic pathways of apoptotic signaling. In the extrinsic pat
initiator caspases (caspase-8) via adaptors, and activate caspase-8 through intermolecul
undergo compartmental changes involving the mitochondrion and endoplasmic reticulum
caspases, either caspase-9 in an apoptosome complex upon release of cytochrome C
interactions. In both extrinsic and intrinsic pathways, activated initiator caspases pro
substrates and cause apoptotic cell death.Mitochondrion- and endoplasmic reticulum-related intrinsic signal
pathways
The apoptotic signaling can also be initiated from inside the
cells in response to stress conditions, e.g. hypoxia or survival factor
deprivation, oncogene activation and DNA damage caused by radi-
ation or chemicals. These intrinsic apoptotic pathways and the
aforementioned extrinsic pathways share downstream signaling
events of apoptosis execution like caspase activation. However,
they are distinguished from the death receptor signaling in that
cells sensor the apoptosis stimuli and activate caspases via differ-
ent mechanisms (Fig. 1).15,26,27
The mitochondrion is crucially involved in the intrinsic apopto-
tic signaling pathways. The permeabilization of mitochondrial out-
er membrane is regulated by proteins of Bcl-2 family, which share
one or more Bcl-2 homology (BH) domains and mediate heterodi-
meric interactions among different members. The Bcl-2 protein
family is further divided as anti-apoptotic and pro-apoptotic pro-
tein subfamilies. The anti-apoptotic proteins like Bcl-2 and Bcl-XL
are located on the surface of the mitochondrion and impede the
activation and homo-oligomerization of the pro-apoptotic Bcl-2
family members, whereas most pro-apoptotic family members,
such as Bax, Bad and Bid, are found in the cytosol and relocate to
the mitochondrial membrane in response to apoptotic stimuli.28,29
The interaction between anti-apoptotic proteins and consequently
the excessive pro-apoptotic proteins result in the formation of
pores on the mitochondria and the release of cytochrome C (Cyt
C) from the intermembrane space. In a multi-protein platform
named apoptosome, the association of cytosol Cyt C with the adap-
tor protein, apoptotic peptidase activating factor 1 (Apaf-1), re-
cruits and activate caspase 9, which sequentially causes the
processing and activation of effector caspases, the degradation of
caspase substrates, and ultimately the collapse of cells.29,30 In addi-
tion, the mitochondrion is involved in a caspase-independent
apoptotic pathway governed by apoptosis-inducing factor (AIF).
AIF is a protein normally located in the intermembrane space ofhway, extracellular death ligands bind and trimerize membrane receptors, recruit
ar autoprocessing of caspases in proximity. In the intrinsic pathway, cells in stress
permeability controlled by the Bcl-2 family, which cause the activation of initiator
, or caspase-12 by disturbed calcium homeostasis prior to a series of molecular
cess and activate effector caspases, which subsequently cleave divergent protein
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to the cytosol and further to the nuclei, where it causes the
destruction of chromosomal DNA (Fig. 1).31
Other organelles also play crucial roles in the self-rising apopto-
tic pathways. Of note is the endoplasmic reticulum (ER), which is
highly sensitive to stresses that perturb cellular energy levels, the
redox state or Ca2+ concentration. Transient ER stress induces un-
folded protein responses (UPR) and promote cell survival, while
prolonged ER stress causes apoptosis via mechanisms yet to be fully
deﬁned.32,33 Nevertheless, the participants of this unique apoptotic
pathway involve the pancreatic ER kinase (PKR)-like ER kinase
(PERK), activating transcription factor 6 (ATF6) and inositol-requir-
ing enzyme 1 (IRE1) in the initiation phase, the transcription factor
C/EBP homologous protein (CHOP), growth arrest andDNAdamage-
inducible gene 34 (GADD34), tribbles-related protein 3 (TRB3) and
Bcl-2 family members in the commitment phase, and ﬁnally
activated caspases for the execution of apoptosis (Fig. 1).32,33Regulators of apoptotic signaling
The apoptosis machinery is precisely regulated by protein
members of varied families. Like the anti-apoptotic members of
Bcl-2 families, the inhibitor of apoptosis (IAP) proteins represent an-
other family negatively regulating apoptosis. IAPs could normally
bind and prevent activation of caspases (Fig. 1).34 In particular, the
X-linked inhibitor of apoptosis (XIAP) binds caspase-9, -3 and -7,
thereby inhibiting their activation and suppressing apoptosis.35 Sur-
vivin, anothermember of IAPs, couldbind andblock the activationof
caspases-3 and -7.36 The second mitochondria-derived activator of
caspase (SMAC)/Diablo and the high temperature requirement
protein-A2 (HTRA2) counteract the effect of IAPs.37 The FLICE-inhib-
itory protein (FLIP) with alternate names Casper/I-FLICE/FLAME-1/
CASH/CLARP/MRI, binds to FADD and caspase-8, and thereby inhib-
its death receptor-mediated apoptosis. As a target gene of NF-jB,
FLIP also dictates the outcome of TNF signaling, i.e. whether cells
continue to survive or undergo apoptosis.38
The generalized apoptosis regulators also comprise particular
oncoproteins and tumor suppressors.39,40 While oncoproteins inhi-
bit apoptosis by elevating signals of cell growth and proliferation,
tumor suppressors could promote apoptosis by attenuating growth
signals or directly acting on the apoptotic machinery. Among its
wide roles in genome stability and cell behaviors, p53 serves as a
sensor of cellular stress and a critical activator of the intrinsic
apoptotic pathway.39 p53 could be phosphorylated and stabilized
by DNA checkpoint proteins in response to DNA damage, and initi-
ate the gene transcription of pro-apoptotic Bcl-2 subfamily, e.g.
Bax and Bid, and other tumor suppressors like phosphatase and
tensin homolog (PTEN). PTEN overexpression leads to apoptosis
via negatively regulating PI3 kinase pathway or by associating with
Bax in the mitochondrion.40Deregulated apoptosis in carcinogenesis
Both the ontogenesis of multicellular organisms and mainte-
nance of normal morphology and function of organs require con-
current cell proliferation and apoptosis, which are balanced by
requisite regulatory mechanism. During carcinogenesis, however,
these mechanisms were disturbed and cells undergo uncontrolled
proliferation while exhibiting resistance to apoptosis. The insufﬁ-
ciency of apoptosis is attributed to either lack of pro-apoptotic
stimuli in the in vivo environment or the blockade of cellular
apoptotic pathways.13,41,42
Neoplastic cells have evolved diverse mechanisms to alter
apoptotic signaling via the extrinsic or intrinsic pathway.13,41,42
The downregulation of Fas or Fas ligand is found in numerousmalignancies, which could be attributed to traditional genetic
mechanisms involving polymorphism or to epigenetic modiﬁca-
tions.43 In osteosarcoma cells, the downregulation of Fas by micr-
oRNA-20a (miR-20a) allow migrating cells to survive and form
metastases in FasL-positive lung microenvironment.44 The expres-
sion of FasL/Fas has thus been implicated in prognosis evaluation
of patients with varied cancers.45 Meanwhile, the expression of
FasL may also be upregulated in cancers, which contributes to
excessive apoptosis of T cells and thus serves as a mechanism of
immune escape.46 The adaptor protein, FADD, also plays multifac-
eted roles in carcinogenesis. FADD downregulation was found in
various cancers like renal cell carcinoma.47 However, it is intrigu-
ing that the upregulation, phosphorylation and nuclear localiza-
tion of FADD are also associated with carcinogenesis and poor
outcome of patients, probably reﬂecting a role of FADD in cell cy-
cle regulation.48 The downregulation of another adaptor, Apaf-1,
was also found to correlate with the progression of certain clinical
malignancies like breast adenocarcinomas.49 As executioners of
apoptosis, caspases are frequently deﬁcient in cancer cells. For
example, caspase-8 is absent in a class of small cell lung
carcinomas, which is predictive of resistance to pro-apoptotic
treatment.50 Somatic caspase-8 mutations have been well-docu-
mented in lung, stomach, breast and pancreatic cancers. Also
reported in cancer tissues are the mutations in the coding or reg-
ulatory regions of caspases-3, -7 and -9, which hamper transcrip-
tion of the genes, disrupt translation of full-length protein or
interfere with the activation of the resulting mutants.51
Bcl-2 family members and regulators of the apoptotic machin-
ery have been found aberrantly expressed or frequently mutated
in carcinoma cells. While overexpression of Bcl-2 or Bcl-xL is asso-
ciated with the development or metastasis of cancers, the absence
or inactivation of the pro-apoptotic Bcl-2 family members, such as
Bax, Bid and Bim is involved in carcinogenesis of varied tissues.52,53
Similarly, overexpression and activation of the apoptosis inhibi-
tors, like XIAP and c-FLIP, are found in neoplastic cells and have
proved a prognostic signiﬁcance in leukemia and other
malignancies.54,55Strategies targeting the apoptotic machinery in carcinoma cells
The deﬁcient apoptotic signaling and thereby the inadequate
apoptosis in cancer cells provide the rationale for gene therapy to
target the apoptotic machinery. In theory, a majority of the mole-
cules involved in apoptotic signaling or regulation can be targeted.
However, since the apoptotic pathways and regulatorymechanisms
are conserved inmammalian cells and common in different types of
human cells of an individual, strategies that constrain the above
molecular targeting to cancer cells are preferably needed.56–58
These cell targeting strategies are so crucial that they can even dic-
tate the outcome of a therapeutic protocol, reminiscent of the cyto-
toxicity and limited success of the prevalent molecule-targeting
anticancer drugs, e.g. the small molecule kinase inhibitors.56,59Molecular targeting: the spear or the shield
Given that deﬁciencies in the apoptosis machinery underlie the
occurrence of numerous carcinomas, it is rational to correct or
compensate for these genetic deﬁciencies in cancer therapy. Nev-
ertheless, the targeting to cellular apoptotic signaling could also
be valid in the treatment of cancers with relatively normal apopto-
sis machinery, considering that this machinery could be utilized for
enforced ‘‘suicide’’ of cancer cells.56,57
The induction of cancer apoptosis is among the most common
approaches in cancer gene therapy or immunotherapy. The gene
encoding an inducer, mediator or executioner of apoptosis is
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its endogenous counterpart.60–62 While theoretically a majority of
the ligand of death receptors can initiate apoptosis, TNF-related
apoptosis-inducing ligand (TRAIL, also designated CD253) is the
most frequently used apoptosis inducer in cancer treatment.63 Be-
cause TRAIL-R1 and TRAIL-R2 are mainly expressed in transformed
cells and the decoy receptors TRAIL-R3, TRAIL-R4 and TRAIL-R5 on
normal cells, TRAIL has been found to kill a wide variety of tumor
cells with minimal effects on adjacent normal cells.24,63 Apoptosis
executioner genes, like caspases, are cytotoxic to cancer cells
regardless of the status of the apoptosis machinery, i.e. whether
there is an inherent defect in the classical apoptotic pathway.20,64
In addition, a proapoptotic gene expression may reverse the malig-
nant phenotype caused by persistent growth signaling, provided
the accumulating data supporting the crosstalk between signals
responsible for cell growth and apoptosis resistance.65–67 In partic-
ular, the epidermal growth factor receptor (EGFR) was found to
upregulate c-FLIP and result in TRAIL resistance via promoting
the expression of tissue transglutaminase (TGM2) in lung can-
cers.67 Conversely, targeting the apoptotic machinery will also con-
tribute to growth and proliferation inhibition in addition to
apoptosis induction in cancer cells.56,60
While an initiative attack of carcinomas by an apoptotic gene
provides a spear against the deﬁcient apoptotic machinery in can-
cer cells, the functional inactivation of the endogenous apoptosis
inhibitors may serve as a shield to prevent the adverse effect of
these molecular abnormalities.68–71 Provided the frequent correla-
tion of carcinogenesis with high levels of these negative regulators
of apoptosis, small inhibitory RNAs like the antisense, siRNAs or
microRNAs can be developed to target these regulators including
the apoptosis inhibitors and Bcl-2 family antiapoptotic members.68
For instance, siRNA-mediated silencing of FLIPL (long form) in neu-
roblastoma cells promotes apoptosis and restored the sensitivity to
other apoptosis inducers like TRAIL and FasL.69 The gene of a dom-
inant negative mutant represents another loss of function strategy
for these apoptosis inhibitors. Of note is the gene of dominant neg-
ative survivin, which induced apoptosis, sensitized cells to proa-
poptotic regents or radiotherapy, and served as a effective
antigen derivation of dendritic cells to elicit antitumor immunity.70
Although not yet applied to apoptosis inhibitors, genes encoding
intracellular antibodies will prove useful in suppression of these
inhibitors in the treatment of related cancers.71Fig. 2. Gene therapy strategies targeting cancer cells. (A) Viral or non-viral carriers were
cells. (B) Geneswere delivered to both cancer and normal cells, but the regulatory elements
cells were modiﬁed to secrete chimeric protein, which targets cancer cells and induces ap
speciﬁc gene expression. Blue lines, constitutive gene regulatory elements; red lines, reguCellular targeting: the devil but not the normal
Since most neoplastic cells share common apoptotic machinery
with normal cells, strategies that target the molecular intervention
to carcinoma cells are required. The targeting of cancer cells in
gene therapy could be achieved in the levels of either gene delivery
or expression. Alternatively, cancer cells can be targeted by a chi-
meric cytotoxic protein secreted by genetically modiﬁed autolo-
gous cells.72–74
Speciﬁc delivery of apoptotic genes in carcinoma cells
The successful delivery of a therapeutic gene is the premise of
in vivo cancer gene therapy. Both viral particles and non-viral car-
riers can be modiﬁed to speciﬁcally recognize cancer cells.75,76 The
viral particles bind host cells via their envelope proteins, which
could be modiﬁed to target carcinoma cells or tumor vascular epi-
thelium. The cell tropism of the wild-type viruses could be modi-
ﬁed by replacing the natural receptor-binding sequence of the
envelope glycoprotein with the peptide recognizing the neovascu-
lar cells, e.g. somatostatin and RGD motif, or with ligands/scFvs
that binds tumor-speciﬁc receptors or antigens (Fig. 2A).77,78 The
viral envelops can also be modiﬁed by charged or surface-modify-
ing polymers like polyethylene glycol (PEG), followed by conjuga-
tion with a tumor-targeting peptide. In terms of this, a hybrid
adeno-associated virus phage vector (AAVP) was developed to tar-
get tumor vasculature through the modiﬁed envelope containing a
av integrin ligand RGD-4C motif. This vector was then used for
delivery of the tumor necrosis factor-a (TNFa) gene, thus reducing
the systemic toxicity of TNFa.79
Non-viral gene carriers, especially the prevalent nanoparticles
consisting of lipid-like materials, are alternate systems for targeted
delivery of apoptotic genes.80–84 Using the recombinant protein
asialoglycoprotein (Asor), which targets asialoglycoprotein recep-
tor (ASGPR) present only on the surface of hepatocytes, Peng
et al.80 generated a target vehicle, and demonstrated that it could
deliver the apoptin gene speciﬁcally into hepatocellular carcinoma
cells, but not normal hepatocytes or malignant cells of other
origins. Fay et al.81 coated the Colloidal nanoparticle with a DR5
antibody, which was used for delivery of cytotoxic drugs, and
found this recombinant carrier could directly trigger apoptosis of
colorectal cancer cells. Goldberg et al.82 used lipidoids to delivermodiﬁed to delivery the apoptotic gene selectively into cancer cells but not normal
allow the expression of the apoptotic gene speciﬁcally in cancer cells. (C) Autologous
optotic cell death. CGE, constitutive gene expression; NGE, no gene expression; SGE,
latory elements enforcing gene expression speciﬁcally in cancer cells.
872 L.-T. Jia et al. / Cancer Treatment Reviews 38 (2012) 868–876siRNAs targeting the Poly (ADP-ribose) polymerase (PARP)-1,
which is a caspase substrate and plays apoptosis-preventing roles
by facilitating repair of damaged DNA. In delivery of hTRAIL gene,
Han et al.83 generated a tumor-targeting carrier, PAMAM-PEG-T7,
consisting of a T7 peptide recognizing the transferrin receptor spe-
ciﬁcally expressed on tumor cells. The T7 peptide was conjugated
to polyethylene glycol-modiﬁed polyamidoamine dendrimer. Lu
et al.84 described a cationic albumin-conjugated pegylated nano-
particles (CBSA-NP), which could deliver the expression cassette
of a given gene like TRAIL across the blood–brain barrier in an
orthotopic glioma model.
Selective expression of apoptosis-triggering genes in carcinoma cells
The efﬁcient expression of a therapeutic gene in target cells is
another pivotal procedure for cancer gene therapy. By replacing
the constitutive promoter with cell type-speciﬁc regulatory ele-
ments, the expression of a gene selectively in cancer cells can be
achieved.73 A tissue-speciﬁc promoter or enhancer is useful to
avoiding undesired expression of the cytotoxic gene in organs or
tissues irrelevant to the primary tumors (Fig. 2B). By placing aden-
oviral E1a, E4 and E1b genes under the control of two individual
Prostate-speciﬁc enhancing sequences, Li et al.85 generated pros-
tate-restricted replicative adenovirus (PRRA). This recombinant
adenovirus was then used to deliver FasL, which is controlled by
the same regulatory elements as the above virus proteins, thereby
achieving the expression speciﬁcity in prostate cells in addition to
the targeted gene delivery.
The regulatory element of an oncogene provides a more reliable
way to express apoptotic gene in cancer cells. In targeted gene
therapy of bladder and prostate cancers, the promoter of Cox-2, a
gene overexpressed in numerous cancer cells, was used to control
the expression of inducible forms of caspases, like caspases-3 and -
9, thereby circumventing the mutation of upstream signals causing
TNF-a resistance.86 Using a glial cell-speciﬁc GFAP promoter com-
bined with Herpes Simplex Virus type 1 (HSV-1)-based amplicon
vector in which the activation of the transgene expression is regu-
lated by a G0/G1-speciﬁc transcriptional repressor protein termed
cell cycle-dependent factor 1, CDF-1, Ho et al.87 achieved both gli-
oma-speciﬁc and cell cycle-dependent expression of the pro-apop-
totic molecules, FasL and FADD.
Unfortunately, small RNAs targeting the apoptosis inhibitory
system normally require the promoters recognized by RNA poly-
merase III (like U6 or H1 promoter) rather than the routine RNA
pol II promoters.88 While shRNAs driven by a tumor-speciﬁc RNA
pol II promoter have recently been developed by replacing the
CMV promoter of commercialized shRNA expressing vectors with
the survivin or stathmin promoter, their efﬁciency to drive shRNA
expression in vivo is still open to further investigation.89 Neverthe-
less, RNA pol II promoter-based small RNA-expressing systems by
embedding the RNA-coding sequence in that of a microRNA have
been developed.90 Alternatively, the shRNA coding sequence could
be inserted in the 30 untranslated region (UTR) of a therapeutic
gene, and coexpressed from a single mRNA to inhibit tumor cell
proliferation or growth.91
Secretion of tumor-targeted proapoptotic proteins by modiﬁed
autologous cells
While routine gene therapy introduces a gene encoding a cellu-
lar protein, it is not uncommon that a therapeutic gene is delivered
to produce a protein which could be secreted and function in the
excellular compartment or by re-entering the cells.61,62 In terms
of cancer gene therapy, a chimeric pro-apoptotic protein can begenerated by fusing a cancer-targeting moiety with an apoptotic-
inducing molecule. Cells, either normal cells or cancer cells them-
selves, can then be genetically modiﬁed to secrete the above pro-
tein (Fig. 2C). This strategy is of particular value when a systemic
treatment is required, for instance, in cases with wide distant
metastasis.92–100
The chimeric genes encoding a class of secreting proapoptotic
proteins have been generated so far by utilizing the tumor-target-
ing characteristics of antibodies or peptides. Li et al.92 described a
lentivirus-mediated modiﬁcation of cells to secrete a chimeric anti-
body targeting the death receptor DR5. The light and heavy chains
of the recombinant antibodywere linked by a 2A/furin self-process-
ing peptide, thereby facilitating its expression from one single vec-
tor and the assembly after cleavage by furin. Tumor-targeted TRAIL
can also be generated by fusing an av integrin ligand peptide RGD-L
to the amino terminal of TRAIL.93 Shah et al.94 constructed recom-
binant TRAILs, which retain in the endoplasmic reticulum and re-
main inactive unless processed by a viral protease, achieving
inducible release of TRAIL and controlled pro-apoptotic activity
and the bystander tumoricidal effects. In contiguous studies
focusing on gene therapy of erbB2/HER2-overexpressing cancers,
Yang’s group74,95–100 generated a series of proapoptotic chimeric
proteins by fusing a single chain antibody against HER2 and active
apoptotic proteins spaced by a translocation domain from natural
protein toxin or a speciﬁc sequence which could be recognized
and processed by furin, a proprotein convertase involved in endo-
some–cytosol translocation of endocytosed proteins. In principle,
these chimeric proteins selectively bind HER2-overexpressing
breast cancer cells and internalize via endocytosis, which is fol-
lowed by cytosol translocation after proteolytic processing by furin.
The released active apoptotic proteins like active caspases and trun-
cated Bid culminate in triggering apoptosis of cancer cells. These
chimeric proteins are advantageous over immunotoxins in that
they kill tumor cells in an intrinsic physiologic manner, resulting
in relatively weak immunogenicity and minor systemic toxicity
over repeated treatments. A fusion gene encoding a signaling
peptide-ﬂanked version of the chimeric proteins was then used to
modify in vivo cells, resulting in production of the protein and
induced apoptosis of carcinoma cells.74,95–100
The secreting proapoptotic protein strategy could be extended
to a further theoretical signiﬁcance when special types of cells
are modiﬁed to secrete the pro-apoptotic proteins. Modiﬁcation
of T lymphocytes with these apoptosis-triggering genes resulted
in the generation of a class of tumor killer cells with characteristics
of both cellular immunity and humoral immunity, given that these
cells could secrete the proapoptotic protein and exert a systemic
tumoricidal effect after homing to the peripheral lymphoid tis-
sues.100,101 Groth et al.102 generated TRAIL-secreting lymphocytes,
which was linked by a bispeciﬁc antibody, EpCAMxCD3, to tumor
cells expressing EpCAM, leading to apoptosis of tumor cells. In
addition, the CD3-recognizing moiety of the bispeciﬁc antibody
also stimulates the proliferation of these modiﬁed lymphocytes,
thus expanding the antitumor effect of lymphocytes. The mesen-
chymal stem cells (MSCs) were modiﬁed by two independent
groups to secrete TRAIL in the treatment of pancreatic cancers
and gliomas, respectively.103,104 Mohr et al.103 generated TRAIL-
secreting MSCs, which could inﬁltrate both tumor and lymphatic
tissues to target primary tumors as well as disseminated cancer
cells in a pancreatic cancer model, and the pro-apoptotic capacity
was further improved by combination with siRNA-mediated
silencing of XIAP. Grisendi et al.105 used modiﬁed adipose-derived
mesenchymal stromal/stem cells (AD-MSC) as a cellular vector of
TRAIL to overcome the short lifespan of recombinant TRAIL protein
in treatment of cervical and pancreatic cancers. In an early study
by Ehtesham et al.,106 neural stem cells were modiﬁed to produce
TRAIL and were reinfused to treat gliomas, which was proved
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via induction of apoptosis.
Clinical trials and perspectives
By virtue of the progress in laboratory studies on cancer gene
therapy targeting the apoptotic machinery, clinicians now have
the opportunities to evaluate the therapeutic potential of a grow-
ing list of pro-apoptotic gene reagents on cancer patients.7,61,62
Due to a confound role of TNF-a in inﬂammation and cancer devel-
opment, it remains a debate whether TNF-a potentially beneﬁts
cancer patients, which has been even complicated by the recent
discovery that TNF-a is critically involved in vascular permeability
regulation. In contrast to the limited success of recombinant TNF-a
protein due to high toxicity, adenovirus-delivered TNF-a,
designated TNFerade, has showed emphatic therapeutic potentials
in advanced, metastatic or recurrent solid tumors including
pancreatic cancer, esophageal cancer, soft tissue sarcoma and mel-
anoma.107–112 A phase III clinical trial combined with chemoradia-
tion (CRT) in locally advanced pancreatic cancer indicated an
encouraging trend of overall survival in favor of the TNF-treated
group compared with CRT alone (Table 1).107 The antitumor capac-Table 1
Clinical cancer gene therapy trials targeting the apoptotic machineries.
Gene Trial ID Trial essentials
TNF-a US-0010 Genetically modiﬁed autologous cancer cells, phase I, clo
US-0399 Adenovirus-delivered, intratumoral, combined with radio
recurrent, or metastatic solid tumors, phase I, closed
US-0457 Adenovirus-delivered, intratumoral, combined with radio
tissue sarcoma, phase I, closed
US-0549 Adenovirus-delivered, intratumoral, combined with chem
for locally advanced esophageal cancer, phase II, open
US-0730 Adenovirus-delivered, intratumoral, combined with radio
phase II, open
US-0750 Adenovirus-delivered, intratumoral, combined with radio
recurrent head and neck cancer, phase I/II, open
NCT00051480 Adenovirus-delivered, intratumoral, combined with radio
cancer, phase II, completed
NCT00051467 Adenovirus-delivered, intratumoral, combined with radio
cancer, phase III, completed
TRAIL US-0603 Adenovirus-delivered, intratumoral, clinically organ conﬁ
radical prostatectomy, phase I, open
Caspase-
9
US-0849 T cells modiﬁed with a caspase-FKBP fusion gene (iCasp9
occurring in relapsed acute leukemia patients receiving h
transplantation, phase I, open
NCT00710892 Allodepleted T cells transduced with inducible caspase 9
leukemia and non-Hodgkin’s lymphoma, phase I, open
NCT01494103 Donor T cells with caspase-9 suicide gene (DOTTI), leuke
Bik NCT00968604 Lipofection-delivered, intravenous, advanced pancreatic
Bcl-2 UK-0130 Naked LNA antisense, relapsed or refractory chronic lym
XIAP UK-0111 Antisense RNA (AEG35156/GEM640), intravenous, advan
UK-0174 AEG35156, combined with chemotherapy, advanced pan
NCT00882869 AEG35156, combined with sorafenib, advanced hepatoce
completed
NCT00558545 AEG35156, combined with paclitaxel, advanced breast ca
NCT00557596 AEG35156, combined with gemcitabine, advanced pancr
NCT00372736 AEG35156, combined with docetaxel, locally advanced, m
phase I, completed
NCT00768339 AEG35156, relapsed or refractory chronic lymphocytic le
lymphomas, phase I/II, terminated due to slow recruitme
NCT00385775 AEG35156, advanced cancers, phase I, terminated due to
dosing in other trials.
NCT01018069 AEG35156, combined with cytarabine and idarubicin, AM
standard dose cytarabine based frontline induction regim
failed to reach endpointsity of the well-documented apoptosis inducer, TRAIL, was also
assessed in phase I/II clinical trials both as a recombinant human
protein or as a therapeutic gene delivered by adenovirus. However,
it is frustrating that the sponsors, Genentech and Amgen, termi-
nated their studies on rhTRAIL after a phase I clinical trials on ad-
vanced cancers. While a phase I study of adenovirus-delivered
TRAIL is still under way for treatment of organ conﬁned prostate
cancer following radical prostatectomy, development of fusion
gene encoding TRAIL conjugated to a tumor-targeting moiety, or
strategies for selective delivery to the neoplastic tissues will deﬁ-
nitely add weight to the opportunity of clinical success.63,113 A con-
stitutively active form of Bcl-2-interacting killer (Bik), which is a
proapoptotic Bcl-2 subfamily member, was demonstrated to syner-
gized with lapatinib in elimination of breast cancer initiating cells,
and has already been involved in a phase I study deciphering its
therapeutic effect on advanced pancreatic cancer (Table 1).114
In parallel with the above gene augmentation strategies, the
inactivation of an anti-apoptotic gene was also addressed clini-
cally. A locked nucleic acid (LNA)-based or phosphorothioate-
modiﬁed antisense molecules against Bcl-2 was approved for
clinical studies in a variety of cancers including relapsed or refrac-
tory lymphocytic leukemia, and have shown promising responseReferences
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Clinical data to be released
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NCT00968604; data not released
phocytic leukemia, phase I/II, open O’Brien et al.116, Moreira et al.68
ced tumors, phase I, open Dean et al.120
creatic cancer, phase I/II, open Tamm123
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874 L.-T. Jia et al. / Cancer Treatment Reviews 38 (2012) 868–876rates with good tolerability.115–118 Also in a phase I/II clinical
studies are the XIAP antisense, namely AEG35156, in treatment
of advanced cancers like pancreatic cancers, and the data concern-
ing patients’ responses remain to be released (Table 1).119–123
Modiﬁcation of cells with apoptotic genes before infusion to hu-
man bodies, i.e. cell therapy, also annotated the role of controlled
apoptosis in clinical cancer gene therapy. In a phase I clinical trial
to treat relapsed acute leukemia, Di Stasi et al. reconstituted pa-
tients’ immune system with genetically modiﬁed donor T cells
mixed with haploidentical stem-cells. These T cells express a fu-
sion protein of caspase-9 and FK-binding protein, which dimerizes,
become activated and commit apoptotic cell death upon treatment
with a small molecule drug, AP-1903. This suicidal mechanism was
then utilized to eliminate the infused cells in case of adverse
events, e.g. the frequently occurring graft-versus-host diseases
(GVHD) in hematopoietic stem cell transplantation.124
Although apoptosis of cancer cells underlies a majority of
conventional therapeutic protocols, gene therapy strategies or
medications directly targeting the apoptotic apparatus are still in
their infancies.3,13,61,62 Despite currently the clear understanding
of the apoptotic signaling has depicted explicit targets for genetic
intervention, the efﬁcacy and safety problem of gene carriers have
impeded the prosperity of proapoptotic gene medicine. A future
breakthrough in the development of gene delivery and expression
systems, which are rigorously neoplastic cell-targeting, applicable
to systemic administration and amenable in formulation to clinical
demands, will bring apoptosis-based cancer gene therapy out of
the embarrassing situation.75,76,93 Nevertheless, while tumor cells
may be removed when exposed to simply cytotoxic reagents,
apoptosis induction is competitively advantageous since apoptotic
cells die autonomously and rarely elicit inﬂammative response or
systemic toxicity.129,130 Provided the characteristics of apoptotic
cell death and progress in related technologies, gene therapy tar-
geting the apoptotic machinery will gain substantial momentum
in the ongoing war towards threatening cancers.Conﬂict of interest statement
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